Pnina Fishman

Founder at CAN-FITE BIOPHARMA LTD.

Net worth: 977 $ as of 2025-05-30

75 year

20 connections

Health Technology

Consumer Services

Health Services

News on Pnina Fishman

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson	Mar. 19	AQ
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient	Mar. 18	AQ
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits	Mar. 03	AQ
Can-Fite BioPharma Ltd. - Special Call	Feb. 25
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25	Feb. 10	AQ
Can Fite BioPharma : anti Obesity Drug Namodenoson Received Patent Allowance in Australia	Nov. 04	PU
Can Fite BioPharma : anti Obesity Drug Namodenoson Received Patent Allowance in Australia Form 6 K	Nov. 04	PU
Can-Fite BioPharma Ltd. - Special Call	24-10-29
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on October 29	24-10-08	AQ
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29	24-10-07	AQ
Can-Fite BioPharma Ltd. - Special Call	24-08-08
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix	24-06-28	BU
Can Fite BioPharma : Other Report or Announcement	24-06-28	PU
Can Fite BioPharma : Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	24-06-24	PU
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	24-06-24	BU
Can-Fite BioPharma Ltd. - Special Call	24-06-06
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases	24-05-29	BU
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6	24-05-23	BU
Can Fite BioPharma : Immediate Report of Meeting	24-05-22	PU
Can Fite BioPharma : NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K	24-05-22	PU
Can Fite BioPharma : Immediate Report	24-05-13	PU
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study	24-05-13	BU
Can-Fite BioPharma Ltd. - Special Call	24-05-11
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies	23-12-20	BU
CAN-FITE ISSUES BUSINESS UPDATE, ALL CLINICAL PROGRAMS AND BUSINESS DEVELOPMENT ACTIVITIES REMAIN SOLIDLY ON TRACK	23-11-02	AQ
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track	23-11-01	BU
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action	23-10-30	BU
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs	23-10-26	BU
CAN-FITE NOVEL APPROACH FOR THE TREATMENT OF PANCREATIC CARCINOMA WITH NAMODENOSON RECEIVES APPRECIATION OF THE AMERICAN ASSOCIATION OF CANCER RESEARCH	23-09-28	AQ
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)	23-09-27	BU
CAN-FITE REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROGRESS IN TWO PIVOTAL PHASE III CLINICAL STUDIES	23-09-01	AQ
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies	23-08-31	BU
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome	23-08-24	BU
CAN-FITE, GRANTED BREAKTHROUGH ABSTRACT AWARD FOR NAMODENOSON IN TREATMENT OF ADVANCED LIVER CANCER BY ASCO CONQUER CANCER FOUNDATION	23-07-18	AQ
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation	23-07-17	BU
CAN-FITE RECEIVES U.S. FDA'S GO AHEAD FOR PICLIDENOSON PSORIASIS REGISTRATION PLAN	23-06-30	AQ
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan	23-06-29	BU
Can Fite BioPharma : NOTICE OF 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 31, 2023 - Form 6-K	23-06-23	PU
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson	23-06-13	BU
Can Fite BioPharma : Namodenoson is out-licensed in China for NASH, projected to become $6.4 billion market by 2027 (Form 6-K)	21-06-16	PU
Can Fite BioPharma : Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update (Form 6-K)	21-05-27	PU
Can Fite BioPharma : Fite's NASH Indication Highlighted in Webinar by KOL Dr. Harrison, 'Namodenoson May Have Big Impact on NASH'	21-01-29	AQ
Can Fite BioPharma : Fite Announces Publication of Namodenoson Liver cer Study in Peer Reviewed Journal-cers	21-01-11	AQ
Can Fite BioPharma : Fite's Namodenoson Abstract Selected as 'Best of The Liver Meeting' in the NASH Category of the Ameri Association of Liver Diseases	20-11-25	AQ
Can Fite BioPharma : Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020	20-11-10	AQ
Can Fite BioPharma : Fite Announces Positive Phase III Psoriasis Interim Data Analysis	20-10-07	AQ
Can Fite BioPharma : Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson's Treatment of NASH at Ameri Association for the Study of Liver Diseases Conference	20-10-01	AQ
Can Fite BioPharma : Clears Can-Fite to Commence Phase II COVID-19 Study	20-09-01	AQ
Can Fite BioPharma : Fite Reports Second Quarter 2020 Financial Results and Provides Clinical Update	20-08-28	AQ
Aug 26, 2020 7:00 AM EDT Can-Fite to Present at The LD Micro 500 Virtual Conference on September 1, 2020	20-08-26	PU

Linked companies

Listed companies	1
CAN-FITE BIOPHARMA LTD.	Health Technology

Private companies	7
OphthaliX, Inc. OphthaliX, Inc. Pharmaceuticals: MajorHealth Technology OphthaliX, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic products for ophthalmic disorders. Its portfolio includes CF101 oral drug that intends to treat glaucoma and uveitis. The company was founded by Ilan Cohn on December 10, 1999 and is headquartered in Petach Tikva, Israel.	Health Technology
Consulting F.D. International Marketing & Engingeering Ltd.
Eyefite Ltd. Eyefite Ltd. BiotechnologyHealth Technology Eyefite Ltd. provides ophthalmology research and develops pharmaceutical products. The company is headquartered in Ramat Gan, Israel.	Health Technology
Ultratrend Ltd.
Rabin Medical Center Beilinson Rabin Medical Center Beilinson Hospital/Nursing ManagementHealth Services Rabin Medical Center Beilinson provides hospital medical services. The private company is based in Petach Tikva, Israel. The CEO of the Israeli company is Eyran Halpern.	Health Services
Mor Research Applications Ltd.
Fd Consulting Ltd.

See company connections

Training of Pnina Fishman

Bar-Ilan University

Doctorate Degree